Related Experiment Video

Updated: Aug 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Functional analysis of PIK3CA gene mutations in human colorectal cancer

Tsuneo Ikenoue1, Fumihiko Kanai, Yohko Hikiba

  • 1Department of Gastroenterology, Graduate School of Medicine, University of Tokyo Hospital, Bunkyo-ku, Japan.

Cancer Research
|June 3, 2005
PubMed

Insights

Mutations in the PIK3CA gene, common in colorectal cancer, enhance lipid kinase activity. These PIK3CA mutations activate key signaling pathways and promote cell transformation, suggesting their role in cancer development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Mutations in the PIK3CA gene, encoding the p110alpha subunit of phosphatidylinositol 3-kinase (PI3K), are implicated in various human cancers.
  • Colorectal cancer frequently harbors PIK3CA mutations, primarily in the helical and kinase domains.
  • While some PIK3CA mutations (e.g., H1047R) show increased activity, the functional impact of other cancer-associated mutations remains largely uncharacterized.

Purpose of the Study:

  • To investigate the functional consequences of colon cancer-associated PIK3CA mutations.
  • To assess the effects of these mutations on lipid kinase activity, downstream signaling, and cellular transformation.

Main Methods:

  • In vitro assessment of lipid kinase activity for eight PIK3CA mutants compared to wild-type p110alpha.
  • In vivo analysis of Akt and p70S6K activation using phospho-specific antibodies via immunoblotting.
  • NIH 3T3 cell transformation assays evaluating morphologic changes, contact inhibition, and anchorage-independent growth.

Main Results:

  • All eight examined PIK3CA mutants exhibited significantly increased lipid kinase activity compared to wild-type.
  • Mutant PIK3CA proteins strongly activated downstream Akt and p70S6K signaling pathways.
  • The mutations induced NIH 3T3 cell transformation, including altered morphology, loss of contact inhibition, and anchorage-independent growth.

Conclusions:

  • Nearly all investigated colon cancer-associated PIK3CA mutations are functionally active, demonstrating elevated enzymatic and transformative capabilities.
  • Hotspot mutations like E542K, E545K, and H1047R possess particularly high activity.
  • These findings strongly suggest that functionally active PIK3CA mutations play a significant role in the process of carcinogenesis.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...